Stockreport
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4 in San Diego. Data on LEQEMBI® (lecanemab-irmb) will include findings on subcutaneous administration for initiation dosing, the benefits of continued therapy and estimated time savings over 10 years of treatment based on Phase 3 clinical data, and real-world experience from a post-marketing observational study in Japan and the ALZ-NET registry. The company will also share new insights into BIIB080, an
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting[GlobeNewswire]
- Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025[PR Newswire]
- New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF[PR Newswire]
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance][Yahoo! Finance]
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
BIIB
SEC Filings
SEC Filings
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- BIIB's page on the SEC website
- More